Longevity has stopped being a Silicon Valley curiosity. Over the past four years, the field has crossed the line from speculative science to institutional industry. Tech billionaires have poured billions into it. Sovereign wealth funds have arrived. The first human trial of partial cellular reprogramming starts this year, with FDA clearance already in hand. A…
